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Unique clinico-biological, genetic and prognostic 
features of adult early T-cell precursor acute 
lymphoblastic leukemia
Early T-cell precursor (ETP) acute lymphoblastic
leukemia (ALL), was first identified within cases of child-
hood T-ALL based on its unique immunophenotypic and
genetic features of limited (early) T-cell differentiation
associated with (some) myeloid and stem cell features.1
Thus ETP-ALL blasts express CD7, dim CD5 (<75% pos-
itive cells), in the absence of CD1a and CD8, and positiv-
ity for ≥1 myeloid/stem cell related markers (i.e., CD34,
CD13 or CD33).1,2 In turn, ETP-ALL frequently shows
myeloid-associated gene alterations such as FLT3,
NRAS/KRAS, DNMT3A, IDH1 and IDH2 mutations,3,4
with lower frequencies of other T-ALL-associated muta-
tions (e.g., NOTCH1 and CDKN2A/B gene mutations).5,6
The World Health Organization (WHO) 2016 classifica-
tion of ALL included ETP-ALL for the first time, as a pro-
visional entity,7 but it failed to establish robust diagnostic
criteria. Thus, after the first immunophenotypic charac-
terization of ETP-ALL by Coustan-Smith et al.1 the pro-
posed criteria did not allow identification of all ETP-ALL
cases as detected by gene expression profiling.2 In addi-
tion, the “partial CD5 expression” criterion had a nega-
tive impact on the reproducibility of ETP-ALL diagnoses
because of the lack of standardization of the method used
for its assessment. Because of this, Zuubier et al. pro-
posed refined immunophenotypic criteria by excluding
CD5 expression while adding negativity for CD4.2
From the clinical point of view early studies based on
limited numbers of pediatric patients indicated that ETP-
ALL was associated with a very poor outcome.1,8,9 More
recent data, based on larger series of children treated
with more intensive therapy, showed no significant dif-
ferences in outcome for ETP-ALL vs. other T-ALL cases.10
In contrast, limited data have been reported for adult
ETP-ALL, with conflicting results.11,12 In one study, adult
ETP-ALL was associated with a worse prognosis follow-
ing different frontline chemotherapy schedules.11 The
GRAALL 2003 and 2005 trials showed that treatment
intensification with allogeneic hematopoietic stem cell
transplantation (HSCT) in ETP-ALL with early treatment
resistance could improve survival.12
Here we retrospectively analyzed the frequency, clini-
co-biological and prognostic features of adult ETP-ALL
vs. other T-ALL cases in a series of 185 adults with T-ALL
treated within two consecutive minimal residual disease-
oriented trials by the Programa Español de Tratamientos en
Hematología (PETHEMA): ALL-HR-2003 (NCT00853008)
and ALL-HR-11  (NCT01540812), the latter still ongo-
ing).
All 185 patients were diagnosed with T-ALL using the
WHO criteria. The treatment protocol schedules have
been described previously elsewhere.13,14 The patients’
characteristics at diagnosis and at follow-up are summa-
rized in Table 1. The immunological T-ALL subtype was
defined according to the European Group for the
Immunological Characterization of Leukemias (EGIL) cri-
teria after centralized review of immunophenotypic
reports. In turn, the criteria proposed by Zuurbier et al.2
were used to define ETP-ALL. The combination of mark-
ers used (<5% CD1a, CD8 and CD4; >25% CD34 and/or
CD33/CD13), resembles that proposed by Coustan-
Smith et al., while dim CD5 expression (<75% positive
cells) was not considered. The inclusion of negativity for
CD4 instead of dim CD5 expression as an immunophe-
notypic criterion, allows identification of most ETP-ALL
cases identified by gene expression profiling (increased
sensitivity of immunophenotyping to detect ETP-ALL
cases).2 Clinical data were obtained in accordance with
the principles of the Declaration of Helsinki and Spanish
legislation, after written informed consent had been pro-
vided by each patient. The study was approved by the
Institutional Review Board of the Hospital Germans Trias
i Pujol (Badalona, Spain).
Comparisons between ETP-ALL and other T-ALL cases
were performed with the χ2 test, Fisher exact test, and the
median test, as appropriate. Event-free survival and over-
all survival curves were plotted using the Kaplan-Meier
method and compared by the log-rank test. A secondary
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Figure 1. Impact of allogeneic hematopoietic stem cell transplantation on overall survival of patients with or without early T-cell precursor acute lymphoblastic
leukemia. (A) Overall survival of adults with early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) vs. other non-ETP T-ALL adult patients censored at
transplantation; the survival probability, with 95% confidence interval (95% CI) at 4 years was 36% (95% CI: 13-59%) for the ETP-ALL group and 49% (95% CI:
39-59%) for the other non-ETP patients. (B) Overall survival of ETP and non-ETP T-ALL patients not censored at transplantation. The survival probability at 4




analysis of overall survival was performed, with trans-
planted patients censored at the time of allogeneic HSCT.
Cumulative incidence of relapse and non-relapse-related
mortality were analyzed as competing events with the
Gray test. A Cox proportional hazard regression model
was used to identify predictive factors for event-free and
overall survival, whereas multivariate analysis for cumu-
lative incidence of relapse was performed with the Fine
and Gray model. Statistical significance was set at P-val-
ues <0.05.
Full immunophenotypic data according to the EGIL cri-
teria were available for 167/185 T-ALL patients; 34/167
(20%) T-ALL cases met criteria for ETP-ALL as defined by
both Zuurbier et al. and the WHO.7 This frequency is sim-
ilar to that observed in previously published cohorts of
adults with T-ALL11,12 in which the phenotypic criteria
applied in early pediatric studies to define ETP-ALL were
used.1 Significant differences were observed when com-
paring ETP-ALL and non-ETP-ALL cases at diagnosis
(Table 1). Patients with ETP traits were older [mean ±
standard deviation (SD): 39±12 years vs. 33±12 years,
P=0.01], more frequently had lymph node enlargement
(79% vs. 56%, P=0.02), had lower white blood cell
counts (mean±SD: 72.2±155.1x109/L vs. 96.6±111.7
x109/L, P=0.004), and showed a slightly different female
to male ratio (13/21 vs. 30/103, P=0.06), similarly to what
has been shown for the GRAALL cohort.12 In addition,
our ETP-ALL cases frequently showed absence of
CDKN2A/B (P<0.001) and TCRG (P=0.003) gene dele-
tions. These results are in line with those previously
reported in the literature6,14,16 and support the use of both
genetic markers for the diagnosis of ETP-ALL. However,
some discordance between immunophenotypic and
genetic results was observed, which might be due to the
limited sensitivity of current immunophenotypic criteria,
highlighting the need for more precise and robust criteria
and standardized methods for the diagnosis of ETP-ALL.
No significant differences in complete response, overall
survival, event-free survival and cumulative incidence of
relapse rates were observed between ETP-ALL patients
enrolled in the two treatment protocols (data not shown).
This allowed a combined evaluation of the data from
both PETHEMA trials. ETP-ALL patients showed signifi-
cantly poorer response to induction therapy compared to
other T-ALL patients (Table 1). Thus, ETP-ALL patients
had poorer bone marrow response (<10% blasts) on day
+14 compared to other T-ALL cases (18% vs. 63%,
P<0.001); half of ETP-ALL cases required second induc-
tion treatment (vs. 10% of the remaining T-ALL cases,
P<0.001) and 23% of them did not attain a complete
response (vs. only 6% of other T-ALL cases, P=0.005).
Minimal residual disease data were available for 132/167
patients who reached a complete resposne after one or
two induction cycles. Two-thirds (65%) of ETP-ALL
cases showed minimal residual disease levels ≥0.1% (vs.
18% of non-ETP-ALL cases, P<0.001), the percentage
increasing to 85% (vs. 37%, P<0.001) at a cut-off level of
0.01%. Consequently, as indicated per protocol, more
ETP-ALL patients underwent allogeneic HSCT (70% vs.
21%, P<0.001). Despite treatment intensification with
allogeneic HSCT, ETP-ALL patients did not attain a sig-
nificant improvement in the probability of overall sur-
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Table 1. Clinico-biological and prognostic characteristics together with response to treatment of early T-cell precursor acute lymphoblastic
leukemia vs. other types of T-cell acute lymphoblastic leukemia.
                                                                       Wholes series                         ETP-ALL                     Other non-ETP T-ALL                         P
                                                                           (n=185)                                (n=34)                                 (n=133)
Age (years)*                                                                    33.5 (12)                                      39 (12)                                         33 (12)                                         0.01
Female/male ratio                                                             49/136                                          13/21                                            30/103                                           0.06
Lymph node enlargement                                         65/163 (40%)                              23/29 (79%)                               66/118 (56%)                                     0.02
Splenomegaly                                                              61/178 (34%)                               8/31 (26%)                                49/130 (38%)                                     0.21
Hepatomegaly                                                              40/175 (23%)                               7/31 (23%)                                30/127 (24%)                                     0.90
Mediastinal mass                                                        86/182 (47%)                                15 (44%)                                  65/131 (50%)                                     0.57
WBC count (x109/L)*                                                   94.3 (121.0)                               72.2 (155.1)                                96.6 (111.7)                                     0.004
CNS involvement                                                         18/178 (10%)                               6/33 (18%)                                 12/130 (9%)                                      0.21
Complex karyotype**                                                  9/141 (6%)                                 3/22 (14%)                                  6/104 (6%)                                       0.19
Del (6q)                                                                         10/140 (7%)                                 1/21 (5%)                                   9/104 (9%)                                       0.47
CDKN2A/B gene deletion                                           31/53 (58%)                                 1/11 (9%)                                  29/40 (73%)                                  <0.001
TCRG gene deletion                                                    24/31 (77%)                                 3/8 (37%)                                  19/20 (95%)                                   0.003
Slow response at day +14                                        82/172 (48%)                              27/33 (82%)                               46/123 (37%)                                 <0.001
1 induction cycle to CR                                             153/167 (92%)                             19/26 (73%)                              118/125 (94%)                               0.003
2 induction cycles to CR                                             14/167 (8%)                                7/26 (27%)                                  7/125 (6%)                                          
CR                                                                                  167/185 (90%)                               26 (77%)                                 125/133 (94%)                                 0.005
MRD day +35 <0.1%                                                  106/141 (75%)                              7/20 (35%)                                90/110 (82%)                                 <0.001
MRD day +35 <0.01%                                                 74/132 (44%)                               3/20 (15%)                                65/104 (63%)                                 <0.001
Chemotherapy                                                             86/121 (71%)                               6/20 (30%)                                 72/91 (79%)                                  <0.001
Allogeneic HSCT                                                         35/121 (29%)                              14/20 (70%)                                19/91 (21%)                                         
Results expressed as number of cases (percentage) or *as a mean (standard deviation). **More than five cytogenetic abnormalities. Minimal residual disease values were
considered only for those patients who reached complete remission. Statistically significant values are shown in bold. ETP: early T-cell precursor; ALL: acute lymphoblastic
leukemia; WBC: white blood cell; CNS: central nervous system; CR: complete remission; MRD: minimal residual disease; HSCT: hematopoietic stem cell transplantation.
vival (Figure 1A, B). In fact, differences in overall and
event-free survival between ETP-ALL and other non-ETP
T-ALL patients were mostly due to the greater rate of fail-
ure to induction therapy, with a minimal contribution of
the higher (non-statistically significant) cumulative inci-
dence of relapse observed among ETP-ALL patients vs.
other T-ALL cases (Online Supplementary Figure S1).
However, it should be noted that the overall survival rate
of adult T-ALL patients from the PETHEMA cohort who
underwent allogeneic HSCT was lower than that
observed in other studies.12,13 Thus, the improvement of
non-transplant-related mortality in transplanted patients
might have a positive impact on survival of 
ETP-ALL patients. Multivariate analyses showed that
ETP-ALL was an independent adverse predictor for both
overall survival and event-free survival [hazard ratio of
2.14 (95% confidence interval: 1.29- 3.53), P=0.003 and
1.91 (1.18-3.11), P=0.009, respectively] together with a
high white blood cell count (Online Supplementary Table
S1).
In summary, here we confirmed the previously report-
ed frequency and clinico-biological features of adult ETP-
ALL and showed that adult ETP-ALL patients should be
considered as a group with a worse prognosis. The poor-
er outcome of ETP-ALL patients in our study was due to
a lower response to induction therapy and not to an
increased relapse rate, which highlights the need to
investigate the potential utility of alternative induction
therapy for these patients. The use of acute myeloid
leukemia-oriented chemotherapy, together with intensi-
fication of chemotherapy regimens, has been effective in
clearing disease in pediatric ETP-ALL cases refractory to
initial induction chemotherapy.17 A similar strategy could
be applied to adult ETP-ALL patients. Based on these
findings, and given the poor response attained in adults
with the conventional induction regimen, it makes sense
to explore the potential benefit of the FLAG-IDA regimen
(idarubicin; fludarabine; ARA-C and granulocyte colony-
stimulating factor), a more myeloid-oriented chemother-
apy schedule, as front-line induction treatment together
with allogeneic HSCT after standard consolidation. In
addition, new therapies targeting specific genes altered in
ETP-ALL patients, such as FLT3 inhibitors, have emerged
as novel alternative treatment strategies. However, the
potential benefit of this latter treatment is restricted to
ETP-ALL patients carrying FLT3mutations in the tyrosine
kinase domain (1/9, ETP-ALL cases in our cohort; data not
shown). Similarly, other potential targeted therapies (e.g.
Jak2 inhibitors or Bcl-2 antagonists) may also provide a
benefit, but require further investigation.
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